Can I Take Folate with AOD-9604?

Why This Combination Raises Questions

Patients exploring AOD-9604 for body composition often already take a daily multivitamin or standalone folate supplement. The question of safety comes up frequently, especially among those with MTHFR variants who rely on methylfolate for proper one-carbon metabolism. Because AOD-9604 is a research-stage peptide without a full FDA-approved label, interaction data is sparse, and that gap creates uncertainty.

The Information Gap Around Peptide-Supplement Pairs

AOD-9604 has not undergone the large-scale Phase III trials that generate comprehensive drug interaction databases. The Natural Medicines Comprehensive Database and Mayo Clinic interaction checker do not list AOD-9604 as an indexed compound. This means there is no formal "interaction monograph" to consult. The absence of a monograph, though, is not evidence of risk. It reflects the regulatory status of AOD-9604 as a 503A compounded peptide rather than a commercially approved drug.

What the Existing Evidence Tells Us

Published preclinical and early clinical data on AOD-9604 focus on its lipolytic mechanism and safety profile in isolation [1][2]. Folate interaction studies exist for drugs that share metabolic enzymes with folate (dihydrofolate reductase inhibitors like methotrexate, anticonvulsants like phenytoin) [3]. AOD-9604 shares none of these enzyme pathways. The two compounds have no overlapping transporter systems, no competitive binding at shared receptors, and no common elimination route that could produce a concentration-dependent conflict.

How AOD-9604 Works in the Body

AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (amino acids 176-191) of human growth hormone, with an added tyrosine residue. It was designed to isolate the lipolytic activity of GH without triggering IGF-1 elevation or the diabetogenic effects of full-length growth hormone [1].

Receptor Targets and Signaling

The peptide stimulates lipolysis through beta-3 adrenergic receptor pathways in adipose tissue. In a 2001 study published in Obesity Research, Heffernan et al. Demonstrated that AOD-9604 increased fat oxidation in obese Zucker rats without altering IGF-1 levels or inducing hyperglycemia [1]. A subsequent Phase IIb human trial (N=300) tested oral AOD-9604 at doses of 1 mg, 5 mg, and 25 mg daily over 12 weeks and found no significant safety signals compared to placebo, though the primary weight-loss endpoint was not met at the oral doses tested [2].

Metabolism and Elimination

As a small peptide (molecular weight ~1,817 Da), AOD-9604 is degraded by endogenous peptidases in plasma and tissue. It does not undergo hepatic cytochrome P450 metabolism. This is a critical distinction: nearly all clinically significant drug-supplement interactions involve CYP450 enzymes, P-glycoprotein transporters, or shared renal tubular secretion. AOD-9604 uses none of these pathways [1][2].

How Folate Works in the Body

Folate (vitamin B9) is a water-soluble B vitamin required for nucleotide synthesis, amino acid metabolism, and methylation reactions. The biologically active form is 5-methyltetrahydrofolate (5-MTHF), which donates a methyl group to homocysteine in the methionine cycle [4].

Absorption and Metabolism

Dietary folate and supplemental folic acid are absorbed in the proximal small intestine via proton-coupled folate transporters (PCFT) [5]. Folic acid (the synthetic form) must be reduced by dihydrofolate reductase (DHFR) before entering the folate cycle. Methylfolate (5-MTHF) bypasses this step entirely. Neither absorption pathway intersects with peptide degradation.

The MTHFR Connection

Approximately 10-15% of the U.S. Population is homozygous for the MTHFR C677T polymorphism, which reduces enzyme activity by about 70% [6]. These individuals convert folic acid to 5-MTHF poorly and may accumulate unmetabolized folic acid in serum. The Endocrine Society and American College of Medical Genetics have both noted that MTHFR genotyping can inform folate supplementation strategy, though routine screening for all patients remains debated [6][7].

For patients taking AOD-9604 who also carry MTHFR variants, the clinical consideration is not about an AOD-9604 interaction. It is about choosing the right form of folate. Methylfolate (L-5-MTHF, 400-1,000 mcg daily) is the preferred form for MTHFR C677T homozygotes [6].

Pharmacokinetic Analysis: No Overlap

A pharmacokinetic interaction occurs when one substance alters the absorption, distribution, metabolism, or excretion of another. For AOD-9604 and folate, each of these parameters operates independently.

Absorption

AOD-9604 is administered subcutaneously and enters systemic circulation through capillary uptake at the injection site. Folate is absorbed orally through PCFT in the jejunum [5]. These are anatomically and mechanistically distinct routes. There is no competition for transporters, no pH-dependent solubility overlap, and no chelation concern (unlike folate with divalent cations like calcium or zinc).

Distribution and Protein Binding

Folate circulates bound to folate-binding proteins and albumin, with a volume of distribution concentrated in the liver [4]. AOD-9604 distributes primarily to adipose tissue and is rapidly cleaved by peptidases. No shared binding proteins have been identified in published literature.

Metabolism

Folate metabolism occurs through the folate cycle (DHFR, MTHFR, methionine synthase) [4]. AOD-9604 metabolism occurs through proteolytic degradation. These are entirely separate enzymatic systems. AOD-9604 does not inhibit or induce any CYP450 isoenzyme, and folate does not affect peptidase activity.

Elimination

Folate is excreted renally, with excess filtered by the glomerulus [4]. AOD-9604 fragments are cleared through peptide catabolism. No shared renal transporter competition exists.

Pharmacodynamic Analysis: No Overlap

A pharmacodynamic interaction occurs when two substances affect the same physiological system in ways that amplify or oppose each other's effects. AOD-9604 and folate act on unrelated systems.

AOD-9604 Targets

AOD-9604 acts on beta-3 adrenergic signaling in white adipose tissue, promoting triglyceride hydrolysis and fatty acid oxidation [1]. It does not affect methylation, nucleotide synthesis, or homocysteine metabolism.

Folate Targets

Folate feeds the one-carbon metabolism cycle, supporting DNA synthesis (thymidylate and purine production), methylation of DNA, RNA, proteins, and lipids, and homocysteine-to-methionine conversion [4]. None of these pathways interact with adrenergic lipolysis.

Bottom Line on Pharmacodynamics

There is no additive toxicity, no opposing effect, and no synergistic risk. Taking both is pharmacodynamically comparable to taking folate alongside any other peptide that does not affect methylation or nucleotide pathways.

When Folate Form Matters More Than AOD-9604 Timing

The most clinically relevant consideration for patients on this combination is not the pairing itself. It is whether the patient is taking the right form and dose of folate for their individual genetics and medication profile.

Folic Acid vs. Methylfolate

For most adults, 400 mcg of folic acid or equivalent dietary folate meets the RDA established by the National Institutes of Health Office of Dietary Supplements [8]. Pregnant individuals need 600 mcg DFE, and those planning pregnancy should begin supplementation at least one month before conception to reduce neural tube defect risk, as confirmed by the U.S. Preventive Services Task Force [9].

Patients with confirmed MTHFR C677T homozygosity or compound heterozygosity (C677T/A1298C) may benefit from L-methylfolate (5-MTHF) at 400-1,000 mcg daily instead of synthetic folic acid [6]. This recommendation is independent of AOD-9604 use.

Anticonvulsant Coprescription

Patients on anticonvulsants such as phenytoin, carbamazepine, or valproate have a well-documented bidirectional interaction with folate. These drugs impair folate absorption and metabolism, while folate supplementation can reduce anticonvulsant serum levels [3][10]. If a patient is taking an anticonvulsant alongside AOD-9604, the folate-anticonvulsant interaction requires monitoring. AOD-9604 does not contribute to this interaction.

The American Academy of Neurology recommends that women of childbearing age on anticonvulsants take at least 0.4 mg of folic acid daily, with some experts suggesting 1-4 mg daily depending on the specific drug and seizure history [10].

Methotrexate and Other DHFR Inhibitors

Patients on methotrexate (for autoimmune conditions or malignancy) require leucovorin (folinic acid) rescue or low-dose folic acid supplementation (1 mg daily) to mitigate mucosal and marrow toxicity [11]. If such a patient is also using AOD-9604, the folate dosing strategy is dictated entirely by the methotrexate protocol. AOD-9604 does not alter methotrexate pharmacokinetics.

Practical Dosing and Administration

No pharmacological basis exists for mandatory dose separation between AOD-9604 and folate. Because AOD-9604 is injected subcutaneously and folate is taken orally, there is no GI-level competition. Patients who prefer a structured routine can separate the two by 30 minutes for psychological comfort, but this is not a clinical requirement.

Suggested Daily Routine

A reasonable approach for patients taking both:

• Morning (fasting): AOD-9604 subcutaneous injection per prescriber protocol (typical research doses range from 250-500 mcg daily)
• With breakfast or any meal: Folate supplement (400-1,000 mcg depending on form and clinical indication)
• No specific food restrictions apply to either compound when used in combination

What to Do If You Are Already Taking Both

If you have been taking folate and AOD-9604 concurrently without adverse effects, there is no reason to change your routine. No case reports, adverse event databases (including FDA MedWatch), or published literature describe an interaction between these two compounds.

Monitoring Recommendations

Standard monitoring for patients on AOD-9604 and folate does not require additional laboratory tests beyond what each compound warrants individually.

For Folate

• Baseline serum folate and red blood cell (RBC) folate if deficiency is suspected
• CBC to assess for megaloblastic changes
• Homocysteine level if MTHFR status is known or cardiovascular risk is elevated
• Recheck at 3 months if supplementation was initiated for deficiency [8]

For AOD-9604

• Fasting glucose and HbA1c at baseline (to track any glycemic effect, though AOD-9604 has shown glucose neutrality in trials) [2]
• Lipid panel at baseline and 8-12 weeks
• IGF-1 level at baseline to confirm the peptide is not elevating growth factor signaling [1]

For the Combination

No additional labs are needed. If a patient reports unexpected bruising, fatigue, or neurological symptoms (paresthesias, cognitive changes), evaluate B12 status. High-dose folic acid can mask B12 deficiency by correcting the megaloblastic anemia while allowing neurological damage to progress [12]. This concern is unrelated to AOD-9604 but relevant to any patient on folate supplementation above 1,000 mcg daily.

Special Populations

Pregnancy and Lactation

AOD-9604 has not been studied in pregnant or lactating humans and should not be used during pregnancy or breastfeeding. Folate supplementation during pregnancy is a standard of care recommended by ACOG (600 mcg DFE daily minimum) [13]. The question of combining these two in pregnancy is moot because AOD-9604 is contraindicated.

Renal Impairment

Folate is renally excreted, and patients with eGFR <30 mL/min may accumulate folate metabolites, though toxicity is rare given folate's water solubility [8]. AOD-9604 is degraded by peptidases and does not require renal dose adjustment based on available data. No combined renal concern has been identified.

Pediatric Patients

Neither AOD-9604 nor folate supplementation (beyond dietary intake) is routinely indicated in pediatric populations for the indications discussed here. Folate supplementation in children follows standard RDA guidelines (150-400 mcg DFE depending on age) [8].